This review paper evaluates recent peer-reviewed research on the potential benefits of cannabis use in the management of rheumatoid arthritis (RA) symptoms. The paper discusses the role of the endocannabinoid system, the analgesic and anti-inflammatory properties of cannabinoids, and the therapeutic potential of cannabis-based medications for RA patients. The paper also highlights the need for further research and clinical trials to determine the optimal treatment approach and establish guidelines for the safe and effective use of cannabis in RA management.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterized by
chronic inflammation of the joints, leading to pain, swelling, and reduced joint function (Firestein & McInnes, 2017). Despite the availability of various pharmacological treatments, many RA patients continue to experience uncontrolled symptoms and seek alternative therapies to alleviate pain and inflammation (Lee & Ruderman, 2019). One such alternative therapy gaining attention is the use of cannabis and its derivatives, which have shown promise in managing RA symptoms (Blake et al., 2006; Fitzcharles et al., 2016). This paper reviews peer-reviewed research on the efficacy of cannabis in improving rheumatoid arthritis symptoms.
The Endocannabinoid System and Rheumatoid Arthritis
The human body possesses an endocannabinoid system (ECS) that modulates various physiological processes, including pain and inflammation (Pertwee, 2006). The ECS comprises endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol, and receptors, notably cannabinoid receptor type 1 (CB1) and type 2 (CB2) (Pacher et al., 2006). Research suggests that the ECS plays a role in RA pathogenesis and that modulating ECS activity may offer therapeutic benefits (Katchan et al., 2016; Richardson et al., 2008).
Analgesic and Anti-inflammatory Properties of Cannabinoids Cannabis contains over 100 cannabinoids, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most widely studied (Borgelt et al., 2013). These cannabinoids interact with CB1 and CB2 receptors, mediating analgesic and anti-inflammatory effects (Pacher et al., 2006). Preclinical studies have demonstrated that THC and CBD can reduce joint inflammation and nociceptive pain in animal models of RA (Lowin et al., 2019; Schuelert & McDougall, 2011).
Cannabis and Rheumatoid Arthritis: Clinical Evidence A limited number of clinical studies have examined the effects of cannabis on RA symptoms. A randomized, double-blind, placebo-controlled trial by Blake et al. (2006) found that a cannabis-based medicine (CBM) containing equal amounts of THC and CBD significantly reduced pain and improved sleep quality in RA patients. Another study by Fitzcharles et al. (2016) reported that RA patients using cannabis experienced improved pain reduction and sleep quality, but also noted the need for further research to establish the safety and efficacy of longterm cannabis use.
Safety and Side Effects
While cannabis may offer symptom relief for some RA patients, it is crucial to consider potential side effects and safety concerns. Short-term side effects
include dizziness, dry mouth, and increased heart rate, while long-term use may lead to cognitive impairment, dependence, and mental health issues (Volkow et al., 2014). Therefore, further studies are needed to determine the risk-benefit ratio of cannabis use in RA management.
Conclusion
Current evidence suggests that cannabis may offer potential benefits in the management of rheumatoid arthritis symptoms, primarily due to its analgesic and anti-inflammatory properties. However, the limited number of clinical studies and the potential side effects associated with cannabis use underscore the need for further research. Future studies should focus on identifying the optimal dosages, formulations, and administration methods, as well as evaluating the long-term safety and efficacy of cannabis use in RA patients. This will help to establish evidence-based guidelines for healthcare providers and RA patients considering cannabis as a treatment option.
References
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45(1), 50-52.
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33(2), 195-209.
Firestein, G. S., & McInnes, I. B. (2017). Immunopathogenesis of rheumatoid arthritis. Immunity, 46(2), 183-196.
Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz, 30(1), 47-61.
Katchan, V., David, P., & Shoenfeld, Y. (2016). Cannabinoids and autoimmune diseases: A systematic review. Autoimmunity Reviews, 15(6), 513-528.
Lee, Y. C., & Ruderman, E. M. (2019). Treatment of rheumatoid arthritis: A review. JAMA, 322(20), 2029-2030.
Lowin, T., Schneider, M., & Pongratz, G. (2019). Joints for joints: cannabinoids in the treatment of rheumatoid arthritis. Current Opinion in Rheumatology, 31(3), 271-278.
Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462.
Pertwee, R. G. (2006). Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology, 147(S1), S163-S171.
Richardson, D., Pearson, R. G., Kurian, N., Latif, M. L., Garle, M. J., Barrett, D. A., … & Chapman, V. (2008). Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Research & Therapy, 10(2), R43.
Schuelert, N., & McDougall, J. J. (2011). The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neuroscience Letters, 500(1), 72-76.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23)
